Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation

The colchicine binding site of tubulin is a promising target for discovering novel antitumour agents. Previously, we identified 2-aryl-4-amide-quinoline derivatives displayed moderate tubulin polymerisation inhibitory activity and broad-spectrum in vitro antitumour activity. In this study, structure...

Full description

Saved in:
Bibliographic Details
Published in:Journal of enzyme inhibition and medicinal chemistry 2023-12, Vol.38 (1), p.2155815-2155815
Main Authors: Liu, Wei, He, Youyou, Guo, Zhongjie, Wang, Miaomiao, Han, Xiaodong, Jia, Hairui, He, Jin, Miao, Shanshan, Wang, Shengzheng
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
antitumour activity
Binding Sites
Cancer therapies
Cell division
Cell Line, Tumor
Cell Proliferation
Clinical trials
Colchicine
Colchicine - chemistry
colchicine binding site
Drug resistance
Drug Screening Assays, Antitumor
Humans
Ligands
Metastasis
Microtubules
Molecular Structure
Motility
Pharmaceutical sciences
Pharmacy
Polymerization
Proteins
Research Paper
structural optimisation
Structure-Activity Relationship
Tubulin
Tubulin - metabolism
Tubulin inhibitors
Tubulin Modulators - chemistry
Tubulin Modulators - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The colchicine binding site of tubulin is a promising target for discovering novel antitumour agents. Previously, we identified 2-aryl-4-amide-quinoline derivatives displayed moderate tubulin polymerisation inhibitory activity and broad-spectrum in vitro antitumour activity. In this study, structure based rational design and systematic structural optimisation were performed to obtain analogues C1∼J2 bearing diverse substituents and scaffolds. Among them, analogue G13 bearing a hydroxymethyl group displayed good tubulin polymerisation inhibitory activity (IC 50  =  13.5 μM) and potent antiproliferative activity (IC 50 values: 0.65 μM∼0.90 μM). G13 potently inhibited the migration and invasion of MDA-MB-231 cells, and displayed potent antiangiogenic activity. It efficiently increased intracellular ROS level and decreased MMP in cancer cells, and obviously induced the fragmentation and disassembly of the microtubules network. More importantly, G13 exhibited good in vivo antitumour efficacy in MDA-MB-231 xenograft model (TGI  =  38.2%; i.p., 30 mg/kg).
ISSN:1475-6366
1475-6374
DOI:10.1080/14756366.2022.2155815